Androgen deprivation delays recurrence of disease but significantly increases the risk of clinically significant spine, hip, and forearm fractures.41–43 Although ETAR antagonists hold promise to reduce the progression of prostate cancer bone metastases, additional morbidity and cost may result owing to an increased fracture risk. This evidence concerns the gene EDNRA and prostate cancer.